Form 4: Intra-Cellular Therapies Director Rory B. Riggs Reports Stock Transactions

Director Rory B. Riggs reports exercising stock options and selling shares of Intra-Cellular Therapies, Inc.

Summary

• On June 23, 2024, Rory B. Riggs acquired 1,567 shares of Intra-Cellular Therapies common stock through the vesting of restricted stock units.
• On June 24, 2024, Riggs exercised options to purchase 20,000 shares at $16.86 per share.
• Also on June 24, 2024, Riggs sold 4,462 shares at $75.57 per share to cover the exercise price of the options.
• Following these transactions, Riggs directly owns 116,600 shares of Intra-Cellular Therapies common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in compliance with SEC regulations.
• The transactions are typical for executives holding stock options and restricted stock units as part of their compensation packages.
• Similar filings can be observed for directors and officers at comparable pharmaceutical companies like Eli Lilly (LLY) or Pfizer (PFE).

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company director.
• The exercise of options and sale of shares could slightly dilute the value of existing shares.

Key Dates